Lunglmayr G
Acta Eur Fertil. 1983 Nov-Dec;14(6):401-4.
The effectiveness of various forms of endocrine treatment for idiopathic oligozoospermia and the action of kallikrein on sperm parameters were evaluated in a retrospective study including 321 individuals with normogonadotropic idiopathic oligozoospermia (sperm count less than 20 Mio/ml). Within a follow up of 3 years 67 conceptions were noted. 51 of them appeared to be treatment-related. The highest conception rate was recorded under tamoxifen. Systemic treatment of idiopathic normogonadotropic oligozoospermia seems to be very limited, since the pathogenetic mechanisms of tubular dysfunction in idiopathic oligozoospermia are still unknown and treatment remains empirical. Spontaneous variations of semen parameters and spontaneous conceptions of the partners of oligospermic males are often responsible for a misinterpretation of the interference of a pharmacological agent with the fertilizing ability of the ejaculate. Development of new treatment regimens and controlled clinical trials are necessary to improve the efficacy of endocrine treatment in idiopathic oligozoospermia.
在一项回顾性研究中，对321例性腺功能正常的特发性少精子症患者（精子计数低于2000万/毫升）评估了各种形式的内分泌治疗对特发性少精子症的有效性以及激肽释放酶对精子参数的作用。在3年的随访中，记录到67例妊娠。其中51例似乎与治疗有关。他莫昔芬治疗下的妊娠率最高。特发性性腺功能正常的少精子症的全身治疗似乎非常有限，因为特发性少精子症中肾小管功能障碍的发病机制仍不清楚，治疗仍为经验性的。少精子症男性精液参数的自发变化以及其配偶的自然受孕常常导致对药物对射精受精能力干扰的误解。开发新的治疗方案和进行对照临床试验对于提高特发性少精子症内分泌治疗的疗效是必要的。
